RESUMO
OBJECTIVE@#This study was conducted to determine the difference of hormone receptor status between pre-menopausal and postmenopausal women diagnosed with invasive ductal carcinoma in the local setting. @*METHODS@#This retrospective descriptive study used data gathered from chart review of premenopausal and postmenopausal female patients diagnosed with invasive ductal carcinoma by tissue biopsy and underwent determination of hormone receptor status (estrogen and progesterone receptor) by immunohistochemical staining (ICA) using biopsy samples taken from June 2016 to December 2019 at Cebu Velez General Hospital, Cebu City. The significance of the difference in the hormone receptor status with menopausal status was analyzed using Fisher’s exact test.@*RESULTS@#Comparing the two groups, 25 (60%) of the pre-menopausal women and 37 (73%) of the post-menopausal women were determined as hormone sensitive, while 17 (40%) pre-menopausal women and 14 (27%) post-menopausal women were hormone resistant. The Fisher’s exact test did not detect a statistically significant difference in the hormone receptor status of pre-menopausal and post-menopausal breast cancer patients.@*CONCLUSION@#There is no significant difference on the hormonal receptor status among pre-menopausal and post-menopausal women diagnosed with invasive ductal carcinoma. Thus, the need for hormone receptor status determination in these patients should be emphasized to aid in proper diagnosis, prognostication, and treatment planning.
RESUMO
Breast carcinoma is the second major killer next to lung carcinoma in female population, and the incidence is on rise. The current study is undertaken to underscore the importance of a low-cost and easy technique like fine-needle aspiration to identify and to grade carcinoma cytologically using Robinson's grading system and Fisher's modification of Black's nuclear grading system and compare with standard Scarff-Bloom-Richardson (SBR) histologic grading system and hormonal receptor status, as these are an important prognostic factor determining the therapy and outcome. The study found that Robinson's cytological grading system is superior to Fischer's modification of Black's nuclear grading, and the former system lined in congruence with the SBR histologic grade of tumour.
RESUMO
Background: The advances in diagnosis and treatment, in the management of breast cancer have led to excellent cure rates for tumors detected in early stage. Even patients with stage III disease have 5 years survival rates in the range of 50-70%. The search for predictive and prognostic factors in breast cancer represents a major challenge. It is important to distinguish prognostic factors from predictive factors. Aim: The aim of the surgery was to compare the immunohistochemical expression of estrogen, progesterone and Her-2 receptor status in breast cancer before and after neo-adjuvant chemotherapy. Materials and methods: In this study, the total of 50 cases of locally advanced breast cancers was included. Cases of carcinoma breast requiring preoperative chemotherapy from January 2015 to January 2017 were recruited in to the study after informed consent. Results: In this study, the total of 50 cases of locally advanced breast cancers was included. Among them most of the cases belonged to the age group of 40 to 60. The extremes of ages (<30 and >60) comprised of only 14 % of the cases. In total of 50 cases 32 patients were pre-menopausal which was accounting for 64% of cases, and remaining patients were post-menopausal. Out of 20 cases of triple negative in this study complete response was seen in 6 cases accounting for about 30%. In our study there were a total of 24 changes in the receptor status post chemotherapy altogether out of which 11 changes were seen in Her2neu group. Changes in the ER and PR group accounted for 8 and 5 cases respectively. Out of 14 cases of ER positive before chemotherapy, conversion was seen in 8 cases accounting for change in ER status of 57%. Similarly 5 changes were seen in PR receptor expression E. Rajesh Goud, M. Muralidhar, M. Srinivasulu. A Study to Evaluate the Effect of Neo-adjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast. IAIM, 2018; 5(9): 83-90. Page 84 accounting for 62% of change. All the changes found were loss of expression of receptor after NACT means receptor positive cases became receptor negative. Conclusion: Breast cancer subtypes are associated with the response to NACT. The response rates for the HE and TN subtypes were significantly higher than for the luminal subtypes. So it is mandatory for a patient with breast cancer who is scheduled for NACT should be assessed for the subtype of breast cancer before NACT, by using IHC, for planning treatment. This study also revealed that change in receptor status did occur after neo-adjuvant chemotherapy.
RESUMO
PURPOSE: The aim of this study was to examine molecular subtype conversions in patients who underwent neoadjuvant chemotherapy (NAC) and analyze their clinical implications. MATERIALS AND METHODS: We included consecutive breast cancer patients who received NAC at the National Cancer Center, Korea, between August 2002 and June 2011, and had available data on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) receptor status prior to NAC. Molecular subtypes, hormone receptor (HR) status, and ER and PR Allred scores before and after NAC were compared, and the long-term outcomes were analyzed. RESULTS: Of 322 patients, 32 (9.9%) achieved a pathologic complete response after NAC. HR+/HER2- tumors tended to convert into triple negative (TN) tumors (10.3%), whereas 34.6% of TN tumors gained HR positivity to become HR+/HER2- tumors. Clinical outcomes of molecular subtype conversion groups were compared against patients who remained as HR+/HER2- throughout. The HR+/HER2- to TN group had significantly poorer recurrence-free survival (RFS) (hazard ratio, 3.54; 95% confidence interval [CI], 1.60 to 7.85) and overall survival (OS) (hazard ratio, 3.73; 95% CI, 1.34 to 10.38). Patients who remained TN throughout had the worst outcomes (for RFS: hazard ratio, 3.70; 95% CI, 1.86 to 7.36; for OS: hazard ratio, 5.85; 95% CI, 2.53 to 13.51), while those who converted from TN to HR+/HER2-showed improved comparable survival outcomes. CONCLUSION: Molecular subtypes of breast cancers changed frequently after NAC, resulting in different tumor prognostication. Tumor subtyping should be repeated after NAC in patients with breast cancer.
Assuntos
Humanos , Neoplasias da Mama , Mama , Tratamento Farmacológico , Fator de Crescimento Epidérmico , Estrogênios , Coreia (Geográfico) , Receptores de ProgesteronaRESUMO
Background: Carcinoma Breast is the most common cancer among females after cervical cancer. An estimated 1 million cases of breast carcinoma have been diagnosed worldwide and it is the leading cause of cancer death among women of age 20-59 years. Aim: The aim of the study is to understand the epidemiological factors and prevalence of different receptor status in cases of Ca breast from the South Indian Population to Govt. Stanley Medical College. Materials and methods: The materials for our retrospective study were collected from the medical records department of Govt. Stanley Medical College (GSMC). All cases of Ca breasts who attended GSMC for admission, treatment, investigations of breast cancer from July 2015 to August 2016 were included in the study. All patients were triple assessed and ER, PR, Her2Neu status were assessed by IHC staining. The study population was grouped based on parameters such as age groups, parity, family history of breast cancer, menopausal status, TNM staging, grade and histological type. Results: In our Study most common age group affected by Ca breast is 41-60 years (57%). 39% of Ca breast cases are premenopausal women. Most common Grade was grade II (41.8%). Most common Histological type was Intra ductal carcinoma about 94.5%. Stage III is common (50.3%). Metastasis was more common in age group > 60years (23%). On comparing stage and grade of tumor 62.8% cases of Stage III were Grade II. Triple Negative cancer is the most common receptor status (25.5%). 57% of triple positive and 57.5% of triple negative cases were in the premenopausal age group. Stage II is the most common presentation in triple positive disease (76.9%). Stage IV is more common in Triple negative patients. K. Muthu Raj MS, S. Mathan Sankar. Epidemiology and receptor status distribution in a cohort of carcinoma breast patients presenting in our institution. IAIM, 2016; 3(12): 75-83. Page 76 Conclusion: In conclusion, our study shows there is an increasing trend of Ca breast in South Indian population among younger and middle age group with Triple Negative Receptors is being most common associated with poor prognostic factors. Hormone receptor status and grading evaluation is needed for targeted therapy
RESUMO
PURPOSE: To investigate correlations of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor type 2 (HER2) statuses with magnetic resonance imaging (MRI) features and clinicohistological characteristics in patients with invasive lobular carcinoma (ILC). MATERIALS AND METHODS: Data from 64 histologically confirmed ILCs were analyzed retrospectively. Preoperative breast MRI was reviewed for morphology and dynamic contrast-enhanced kinetics of the tumor. Pathologic reports were reviewed for ER, PR, and HER2 positivity, tumor size, lymph node metastasis, and the number of metastatic lymph nodes. Furthermore, there was an investigation of the MRI features and clinicohistologic characteristics, according to the ER, PR, and HER2 statuses. RESULTS: A significant difference in MRI features and clinicohistological tumor characteristics were observed only in relation to PR status. Of the 64 ILCs, 10 (15.6%) were PR negative. PR negative cancers, compared with PR positive cancers, were more likely to present as non-mass enhancement (P = 0.027); have a significantly larger mean tumor size (5.00 +/- 1.05 cm vs. 2.57 +/- 0.21 cm, P = 0.021); and have significantly more metastatic lymph nodes (P = 0.010). CONCLUSIONS: PR negative ILC presented more frequently as non-mass enhancement on MRI, with larger tumors and increased numbers of metastatic lymph nodes. Therefore, the PR status plays an important role in determining MRI features and clinicohistological characteristics of ILC.